Study of gut bacteria in liver cancer treated with TKI + immunotherapy
Part of Cancer, Digestive system clinical trials.
This trial tests how a combination of targeted therapy (TKI) and immunotherapy (ICI) affects the gut bacteria in people with advanced liver cancer that cannot be surgically removed. It aims to see if changes in the microbiome can help predict treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have liver cancer (HCC) that cannot be removed by surgery and is at an advanced stage (B or C).
- You have not had any previous cancer treatment that goes through your whole body (like chemotherapy, targeted pills, or immunotherapy).
- Your doctor plans to treat you with a combination of a targeted therapy (TKI) and an immunotherapy (ICI).
- Your liver function is good (Child-Pugh grade A), your overall health is fairly good (ECOG 0 or 1), and you have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how gut bacteria affect liver cancer treatment. It is for people whose liver cancer worsened after certain targeted and immunotherapy drugs.
This study is for people with advanced liver cancer who are starting a new type of treatment that combines targeted therapy to block blood vessel growth and immune therapy to help your body fight the cancer. It looks at how gut bacteria might affect treatment response.
This study looks at how the gut microbiome affects treatment response in patients with advanced liver cancer who are receiving immunotherapy. It involves a colonoscopy to collect samples and may help improve future treatments.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.